Drugs / DS-8895a
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02252211 | Dec 2014 → Sep 2016 | cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT02004717 | Oct 2013 → Feb 2017 | cancer | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-8895a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02252211 ↗ |
| Modality | Monoclonal antibody | “DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance antibody-dependent cellular cytotoxicity activity.” PMID 31412935 ↗ Aug 2019 |
| Route | Intravenous | “DS-8895a was intravenously administered every 2 weeks for the duration of the study, with a 28-day period to assess dose-limiting toxicity (DLT).” PMID 31412935 ↗ Aug 2019 |
| Target | EPHA2 | “DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance antibody-dependent cellular cytotoxicity activity.” PMID 31412935 ↗ Aug 2019 |